Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptase

AIDS Reviews

Volumn 7, Issue 2, 2005, Pages 113-125

  Ray, Adrian S ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

Drug interactions; HAART; HIV; In vitro; Metabolism; NRTI

Indexed keywords

2' DEOXYNUCLEOSIDE; ABACAVIR; CARBOVIR; DIDANOSINE; DRUG METABOLIZING ENZYME; LAMIVUDINE; NUCLEOSIDE TRIPHOSPHATE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CELL CULTURE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TRANSPORT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MASS SPECTROMETRY; REVIEW;

DRUG SYNERGISM; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MOLECULAR STRUCTURE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 23144439258     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (165)

1. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. 2004. (Accessed Dec 29, 2004, at http://www.aidsinfo.nih.gov/guidelines/default_db2.asp?id=50)
2. Balzarini J. Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives. Pharm World Sci 1994;16:113-26.
3. Sommadossi J. Cellular nucleoside pharmacokinetics and pharmacology: a potentially important determinant of antiretroviral efficacy. AIDS 1998;12 (Suppl 3):1-8.
4. Stein D, Moore K. Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians. Pharmacotherapy 2001;21:11-34.
5. Anderson P, Kakuda T, Lichtenstein K. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis 2004;38:743-53.
6. Sharma P, Nurpeisov V, Hernandez-Santiago B, Beltran T, Schinazi R. Nucleoside inhibitors of HIV type 1 reverse transcriptase. Curr Top Med Chem 2004;4:895-919.
7. Pillero P. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2004;37 (Suppl 1):2-12.
8. Anderson P, Kakuda T, Kawle S, Fletcher C. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 2003;17:2159-68.
9. Stretcher B, Pesce A, Frame P, Stein D. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV. Antimicrob Agents Chemother 1994;38:1541-7.
10. Cass C, Young J, Baldwin S, et al. Nucleoside transporters of mammalian cells. Pharm Biotechnol 1999;12:313-52.
11. Cooney D, Dalal M, Mitsuya H, et al. Initial studies on the cellular pharmacology of 2′,3-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol 1986;35:2065-8.
12. Ullman B, Coons T, Rockwell S, McCartan K. Genetic analysis of 2′,3′-dideoxycytidine incorporation into cultured human T lymphololasts. J Biol Chem 1988;263:12391-6.
13. Rahn J, Kieller D, Tyrrell D, Gati W. Modulation of the metabolism of beta-L-(-)-2′,3′-dideoxy-3′-thiacytidine by thymidine, fludarabine, and nitrobenzylthioinosine. Antimicrob Agents Chemother 1997;41:918-23.
14. Paff M, Averett D, Prus K, Miller W, Nelson D. Intracellular metabolism of (-)- and (+)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (subclone P5A) cells. Antimicrob Agents Chemother 1994;38:1230-8.
15. Schuetz J, Connelly M, Sun D, et al. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999;5:1048-51.
16. Turriziani O, Schuetz J, Focher F, et al. Impaired 2′,3′-dideoxy-3′-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrug resistant protein 4 with a possible role for ATP-binding cassette C11. Biochem J 2002;368:325-32.
17. Hoggard P, Back D. Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules. Curr Opin Infect Dis 2002;15:3-8.
18. Borst P, Balzarini J, Ono N, et al. The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy. Antiviral Res 2004;62:1-7.
19. Avramis V, Kwock R, Solorzano M, Gomperts E. Evidence of in vitro development of drug resistance to azidothymidine in T-lymphocytic leukemia cell lines (Jurkat E6-1/AZT-100) and in pediatric patients with HIV-1 infection. J Acquir Immune Defic Syndr 1993;6:1287-96.
20. Magnani M, Brandi G, Casablanca A, et al. 2′,3′-Dideoxycytidine metabolism in a new drug-resistant cell line. Biochem J 1995;312 (Pt 1):115-23.
21. Antonelli G, Turriziani O, Verri A, et al. Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of phosphorylation of thymidine kinase. AIDS Res Hum Retroviruses 1996;12:223-8.
22. Ahluwalia G, Cooney D, Mitsuya H, et al. Initial studies on the cellular pharmacology of 2′,3′-dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol 1987;36:3797-800.
23. Faletto M, Miller W, Garvey E, St Clair M, Daluge S, Good S. Unique intracellular activation of the potent anti-HIV agent 1592U89. Antimicrob Agents Chemother 1997;41:1099-107.
24. Van Rompay A, Johansson M, Karlsson A. Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases. Pharmacol Ther 2000;87:189-98.
25. Schneider B, Sarfati R, Deville-Bonne D, Veron M. Role of nucleoside diphosphate kinase in the activation of anti-HIV nucleoside analogs. J Bioenerg Biomembr 2000;32:317-24.
26. Krishnan P, Fu Q, Lam W, Liou J, Dutschman G, Cheng Y. Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: selective phosphorylation of L-nucleoside analog diphosphates by 3-phosphoglycerate kinase. J Biol Chem 2002;277:5453-9.
27. Balzarini J, Pauwels R, Baba M, et al. The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3′-azido-2′,3′-dideoxythymidine and 2′,3′-dideoxycytidine are highly dependent on the cell species. Biochem Pharmacol 1988;37:897-903.
28. Perno C, Cooney D, Gao W, et al. Effects of bone marrow stimulatory cytokines on HIV replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages. Blood 1992;80:995-1003.
29. Perno C, Aquaro S, Rosenwirth B, et al. In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages. J Leukoc Biol 1994;56:381-6.
30. Gao W, Shirasaka T, Johns D, Broder S, Mitsuya H. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993;91:2326-33.
31. Gao W, Agbaria R, Driscoll J, Mitsuya H. Divergent anti-HIV activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem 1994;269:12633-8.
32. Munch-Petersen B, Cloos L, Tyrsted G, Eriksson S. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem 1991;266:9032-8.
33. Bestwick R, Mathews C. Unusual compartmentation of precursors for nuclear and mitochondrial DNA in mouse L cells. J Biol Chem 1982; 257:9305-8.
34. Saada-Reisch A. Deoxyribonucleoside kinases in mitochondrial DNA depletion. Nucleosides Nucleotides Nucleic Acids 2004;23:1205-15.
35. Sjoberg A, Wang L, Eriksson S. Substrate specificity of human recombinant mitochondrial deoxyguanosine kinase with cytostatic and antiviral purine and pyrimidine analogs. Mol Pharmacol 1998;53:270-3.
36. Zhu C, Johansson M, Permert J, Karlsson A. Enhanced cytotoxicity of nucleoside analogs by overexpression of mitochondrial deoxyguanosine kinase in cancer cell lines. J Biol Chem 1998;273:14707-11.
37. Cui L, Locatelli L, Xie M, Sommadossi J. Effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells. J Pharmacol Exp Ther 1997;280:1228-34.
38. Chen C, Cheng Y. The role of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the anti-HIV compound, 2′,3′-dideoxycytidine. J Biol Chem 1992;267:2856-9.
39. Dolce V, Fiermonte G, Runswick M, Palmieri F, Walker J. The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals. Proc Natl Acad Sci U S A 2001;98:2284-8.
40. Sales S, Hoggard P, Sunderland D, Khoo S, Hart C, Back D. Zidovudine phosphorylation and mitochondrial toxicity in vitro. Toxicol Appl Pharmacol 2001;177:54-8.
41. Kakuda T. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000;22:685-708.
42. Ziagen Prescribing Information. (Accessed August 8, 2004, at http://www.gsk.com/products/ziagen_us.htm)
43. Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 1953;3:285-90.
44. Machado S, Robinson G. A direct, general approach based on isobolograms for assessing the joint action of drugs in pre-clinical experiments. Stat Med 1994;13:2289-309.
45. Belen'kii M, Schinazi R. Multiple drug effect analysis with confidence interval. Antiviral Res 1994;25:1-11.
46. Selleseth D, Talarico C, Miller T, Lutz M, Biron K, Harvey R. Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication. Antimicrob Agents Chemother 2003;47:1468-71.
47. Prichard M, Shipman C. Analysis of combinations of antiviral drugs and design of effective multidrug therapies. Antivir Ther 1996;1:9-20.
48. Tallarida R, Stone D, McCary J, Raffa R. Response surface analysis of synergism between morphine and clonidine. J Pharmacol Exp Ther 1999;289:8-13.
49. Tallarida R. Drug Synergism and Dose-Effect Data Analysis. 1 ed. New York: Chapman and Hall/CRC; 2000.
50. Bridges E, Dutschman G, Gullen E, Cheng Y. Favorable interaction of beta-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of HIV. Biochem Pharmacol 1996;51:731-6.
51. Dutschman G, Bridges E, Liu S, et al. Metabolism of 2′,3′-dideoxy-2′,3′-didehydro-beta-L(-)-5- fluorocytidine and its activity in combination with clinically approved anti-HIV beta-D(+) nucleoside analogs in vitro. Antimicrob Agents Chemother 1998;42:1799-804.
52. White E, Parker W, Ross L, Shannon W. Lack of synergy in the inhibition of HIV-1 reverse transcriptase by combinations of the 5′-triphosphates of various anti-HIV nucleoside analogs. Antiviral Res 1993;22:295-308.
53. Villahermosa M, Martinez-Irujo J, Cabodevilla F, Santiago E. Synergistic inhibition of HIV-1 reverse transcriptase by combinations of chain-terminating nucleotides. Biochemistry 1997;36:13223-31.
54. Veal G, Barry M, Khoo S, Back D. In vitro screening of nucleoside analog combinations for potential use in anti-HIV therapy. AIDS Res Hum Retroviruses 1997;13:481-4.
55. Hoggard P, Sales S, Kewn S, et al. Correlation between intracellular pharmacological activation of nucleoside analogues and HlV suppression in vitro. Antivir Chem Chemother 2000;11:353-8.
56. Balzarini J, Cooney D, Dalal M, et al. 2′,3′-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis. Mol Pharmacol 1987;32:798-806.
57. Johnson M, Johns D, Fridland A. 2′,3′-Dideoxynucleoside phosphorylation by deoxycytidine kinase from normal human thymus extracts: activation of potential drugs for AIDS therapy. Biochem Biophys Res Commun 1987;148:1252-8.
58. Chang C, Skalski V, Zhou J, Cheng Y. Biochemical pharmacology of (+)- and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J Biol Chem 1992;267:22414-20.
59. Shewach D, Liotta D, Schinazi R. Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2′-deoxycytidine kinase. Biochem Pharmacol 1993;45:1540-3.
60. Ho H, Hitchcock M. Cellular pharmacology of 2′,3′-dideoxy-2′,3′-didehydrothymidine, a nucleoside analog active against HIV. Antimicrob Agents Chemother 1989; 33:844-9.
61. Hoggard P, Khoo S, Barry M, Back D. Intracellular metabolism of zidovudine and stavudine in combination. J Infect Dis 1996;174:671-2.
62. Hoggard P, Kewn S, Barry M, Khoo S, Back D. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 1997;41:1231-6.
63. Marongiu M, August E, Prusoff W. Effect of 3′-deoxythymidin-2′-ene (d4T) on nucleoside metabolism in H9 cells. Biochem Pharmacol 1990;39:1523-8.
64. Hitchcock M. Review: antiviral portrait series, number 1 2′,3′-didehydro-2′,3′-dideoxythymidine (D4T), an anti-HIV agent. Antivir Chem Chemother 1991;2:125-32.
65. Turriziani O, Antonelli G, Verri A, et al. Alteration of thymidine kinase activity in cells treated with an antiviral agent. J Biol Regul Homeost Agents 1995;9:47-51.
66. Balzarini J, Herdewijn P, De Clercq E. Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, two potent anti-HIV compounds. J Biol Chem 1989;264:6127-33.
67. Furman P, Fyfe J, St Clair M, et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with HIV reverse transcriptase. Proc Natl Acad Sci USA 1986;83:8333-7.
68. Avramis V, Markson W, Jackson R, Gomperts E. Biochemical pharmacology of zidovudine in human T-lymphoblastoid cells (CEM). AIDS 1989;3:417-22.
69. Robbins B, Wilcox C, Fridland A, Rodman J. Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells. Pharmacotherapy 2003;23:695-701.
70. Mulato A, Cherrington J. Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses. Antiviral Res 1997;36:91-7.
71. Ray A, Olson L, Fridland A. Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob Agents Chemother 2004;48:1089-95.
72. Stein J, Stoeckler J, Li S, et al. Inhibition of human purine nucleoside phosphorylase by acyclic nucleosides and nucleotides. Biochem Pharmacol 1987;36:1237-44.
73. Tuttle J, Krenitsky T. Effects of acyclovir and its metabolites on purine nucleoside phosphorylase. J Biol Chem 1984;259:4065-9.
74. Beauchamp L, Tuttle J, Rodriguez M, Sznaidman M. Guanine, pyrazolo[3,4-d]pyrimidine, and triazolo[4,5-d]pyrimidine (8-azaguanine) phosphonate acyclic derivatives as inhibitors of purine nucleoside phosphorylase. J Med Chem 1996;39:949-56.
75. Kulikowska E, Bzowska A, Holy A, Magnowska L, Shugar D. Antiviral acyclic nucleoside phosphonate analogues as inhibitors of purine nucleoside phosphorylase. Adv Exp Med Biol 1998;431:747-52.
76. Wierzchowski J, Kulikowska E, Bzowska A, Holy A, Magnowska L, Shugar D. Interactions of calf spleen purine nucleoside phosphorylase with antiviral acyclic nucleoside phosphonate inhibitors: kinetics and emission studies. Nucleosides Nucleotides 1999;18:875-6.
77. Stoeckler J, Cambor C, Parks R. Human erythrocytic purine nucleoside phosphorylase: reaction with sugar-modified nucleoside substrates. Biochemistry 1980;19:102-7.
78. Baba M, Pauwels R, Balzarini J, Herdewijn P, De Clercq E, Desmyter J. Ribavirin antagonizes inhibitory effects of pyrimidine 2′,3′-dideoxynucleosides but enhances inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of HIV in vitro. Antimicrob Agents Chemother 1987;31:1613-7.
79. Vogt M, Hartshom K, Furman P, et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987;235:1376-9.
80. Hoggard P, Veal G, Wild M, Barry M, Back D. Drug interactions with zidovudine phosphorylation in vitro. Antimicrob Agents Chemother 1995;39:1376-8.
81. Klein M, Campeol N, Lalonde R, Brenner B, Wainberg M. Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus. AIDS 2003;17:1001-8.
82. Havlir D, Tierney C, Friedland G, et al. In vivo antagonism with zidovudine plus stavudine combination therapy. J Infect Dis 2000;182:321-5.
83. Kearney B, Flaherty J, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004;43:595-612.
84. Kewn S, Veal G, Hoggard P, Barry M, Back D. Lamivudine (3TC) phosphorylation and drug interactions in vitro. Biochem Pharmacol 1997;54:589-95.
85. Staszewski S. Zidovudine and lamivudine: results of phase III studies. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10 (Suppl 1):57.
86. Larder B, Kemp S, Harrigan P. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269:696-9.
87. Bethell R, Adams J, De Muys J, et al. Pharmacological evaluation of a dual deoxycytidine analogue combination: 3TC and SPD754. In: 11th Conference on Retroviruses and Opportunistic Infections; 2004 February 8-11; San Francisco, CA, USA; 2004.
88. Ahluwalia G, Cooney D, Bondoc L, et al. Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the antiviral nucleoside 2′,3′-dideoxyguanosine. Biochem Biophys Res Commun 1990; 171:1297-303.
89. Balzarini J. Effect of antimetabolite drugs of nucleotide metabolism on the anti-HIV activity of nucleoside reverse transcriptase inhibitors. Pharmacol Ther 2000;87:175-87.
90. Moore E, Hurlbert R. Regulation of mammalian deoxyribonucleotide biosynthesis by nucleotides as activators and inhibitors. J Biol Chem 1966;241:4802-9.
91. Eriksson S, Thelander L, Akerman M. Allosteric regulation of calf thymus ribonucleoside diphosphate reductase. Biochemistry 1979;18:2948-52.
92. Nyce J. Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer Res 1989;49:5829-36.
93. Stretcher B, Pesce A, Murray J, Hurtubise P, Vine W, Frame P. Concentrations of phosphorylated zidovudine (ZDV) in patient leukocytes do not correlate with ZDV dose or plasma concentrations. Ther Drug Monit 1991;13:325-31.
94. Nyce J, Leonard S, Canupp D, Schulz S, Wong S. Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance. Proc Natl Acad Sci USA 1993;90:2960-4.
95. Jacobsson B, Britton S, He Q, Karlsson A, Eriksson S. Decreased thymidine kinase levels in peripheral blood cells from HIV-seropositive individuals: implications for zidovudine metabolism. AIDS Res Hum Retroviruses 1995;11:805-11.
96. Lucarelli M, Palitti F, Carotti D, et al. AZT-induced hypermethylation of human thymidine kinase gene in the absence of total DNA hypermethylation. FEBS Lett 1996;396:323-6.
97. Turriziani O, Antonelli G, Focher F, Bambacioni F, Dianzani F. Further study of the mechanism underlying the cellular resistance to AZT. Biochem Biophys Res Commun 1996;228:797-801.
98. McKee E, Bentley A, Hatch M, Gingerich J, Susan-Resiga D. Phosphorylation of thymidine and AZT in heart mitochondria: elucidation of a novel mechanism of AZT cardiotoxicity. Cardiovasc Toxicol 2004;4:155-67.
99. Frick L, Nelson D, St Clair M, Furman P, Krenitsky T. Effects of 3′-azido-3′-deoxythymidine on the deoxynucleotide triphosphate pools of cultured human cells. Biochem Biophys Res Commun 1988;154:124-9.
100. De la Asuncion J, del Olmo M, Sastre J, et al. AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins. J Clin Invest 1998;102:4-9.
101. De la Asuncion J, del Olmo M, Sastre J, Pallardo F, Vina J. Zidovudine (AZT) causes an oxidation of mitochondrial DNA in mouse liver. Hepatology 1999;29:985-7.
102. De la Asuncion J, del Olmo M, Gomez-Cambronero L, Sastre J, Pallardo F, Vina J. AZT induces oxidative damage to cardiac mitochondria: protective effect of vitamins C and E. Life Sci 2004;76:47-56.
103. White A. Mitochondrial toxicity and HIV therapy. Sex Transm Infect 2001;77:158-73.
104. Lim S, Copeland W. Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma. J Biol Chem 2001;276:23616-23.
105. Johnson A, Ray A, Hanes J, et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 2001;276:40847-57.
106. Barrios A, Rendon A, Negredo E, et al. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS 2005;19:569-75.
107. Blanchard J, Wohlfeiler M, Canas A, King K, Lonergan J. Pancreatitis with didanosine and tenofovir disoproxil fumarate. Clin Infect Dis 2003;37:e57-62.
108. Gallant J, Rodriguez A, Wieinberg W, et al. Early non-response to tenofovir-DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis. In: 43rd International Conference on Antimicrobial Agents and Chemotherapy; 2003 September 14-17; Chicago, IL: American Chemical Society; 2003. p. abstract H-17722a.
109. Farthing C, Khanlou H, Yeh V, Harris G. Early virologic failure in a pilot study evaluating the efficacy of once daily abacavir (ABC), lamivudine (3TC) and tenofovir DF (TDF) in treatment naive HIV-infected patients. In: Second International AIDS Society Conference on HIV Pathogenesis and Treatment; 2003 July 13-16; Paris, France: International AIDS Society; 2003. p. S195.
110. Hoogewerf M, Regez R, Schouten W, Weigel H, Frissen P, Brinkman K. Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression. Lancet 2003;362:1979-80.
111. Kakuda T, Anderson P, Becker S. CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related. AIDS 2004;18:2442-4.
112. Bzowska A, Kulikowska E, Shugar D. Purine nucleoside phosphorylases: properties, functions, and clinical aspects. Pharmacol Ther 2000;88:349-425.
113. Bantia S, Ananth S, Parker C, Horn L, Upshaw R. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor-BCX1777. Int Immunopharmacol 2003;3:879-87.
114. Stoeckler J, Ealick S, Bugg C, Parks R. Design of purine nucleoside phosphorylase inhibitors. Fed Proc 1986;45:2773-8.
115. Lewandowicz A, Tyler P, Evans G, Furneaux R, Schramm V. Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase. J Biol Chem 2003;278:31465-8.
116. Kearney B, Isaacson E, Sayre J, Ebrahimi R, Cheng A. The pharmacokinetics of abacavir, a purine nucleoside analogue, are not affected by tenofovir DF. In: 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 September 14-17; Chicago, IL: American Chemical Society; 2003. p. A-1615.
117. Hawkins T, Veikley W, StClaire R, Hey A, Guyer B, Kearney S. Intracellular pharmacokinetics of tenofovir-DP and carbovir-TP in patients receiving triple nucleoside regimens. In: 5th International Workshop on Clinical Pharmacology of HIV Therapy; 2004 April 1-3; Rome, Italy: Virology Education; 2004. p5.
118. Ray A, Myrick F, Vela J, et al. Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine. Antiviral Ther 2005;10:451-7.
119. Ray A, Vela J, Olson L, Fridland A. Effective metabolism and long intracellular half life of the anti-hepatitis B agent adefovir in hepatic cells. Biochem Pharmacol 2004;68:1825-31.
120. Moore J, Valette G, Darque A, Zhou X, Sommadossi J. Simultaneous quantitation of the 5′-triphosphate metabolites of zidovudine, lamivudine, and stavudine in peripheral mononuclear blood cells of HIV infected patients by high-performance liquid chromatography tandem mass spectrometry. J Am Soc Mass Spectrom 2000;11:1134-43.
121. Font E, Rosario O, Santana J, Garcia H, Sommadossi J, Rodriguez J. Determination of zidovudine triphosphate intracellular concentrations in peripheral blood mononuclear cells from HIV-infected individuals by tandem mass spectrometry. Antmicrob Agents Chemother 1999;43:2964-8.
122. Shi G, Wu J, Li Y, et al. Novel direct detection method for quantitative determination of intracellular nucleoside triphosphates using weak anion exchange liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2002;16:1092-9.
123. Witters E, Van Dongen W, Esmans E, Van Onckelen H. Ion-pair liquid chromatography-electrospray mass spectrometry for the analysis of cyclic nucleotides. J Chromatogr B Biomed Sci Appl 1997;694:55-63.
124. St. Claire R. Positive ion electrospray ionization tandem mass spectrometry coupled to ion-pairing high-performance liquid chromatography with a phosphate buffer for the quantitative analysis of intracellular nucleotides. Rapid Commun Mass Spectrom 2000;14:1625-34.
125. Pruvost A, Becher F, Bardouille P, et al. Direct determination of phosphorylated intracellular anabolites of stavudine (d4T) by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2001;15:1401-8.
126. Fung E, Cai Z, Burnette T, Sinhababu A. Simultaneous determination of Ziagen and its phosphorylated metabolites by ion-pairing high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 2001;754:285-95.
127. Becher F, Schlemmer D, Pruvost A, et al. Development of a direct assay for measuring intracellular AZT triphosphate in humans peripheral blood mononuclear cells. Anal Chem 2002;74:4220-7.
128. Becher F, Pruvost A, Goujard C, et al. Improved method for the simultaneous determination of d4T, 3TC and ddl intracellular phosphorylated anabolites in human peripheral-blood mononuclear cells using high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2002;16:555-65.
129. Tuytten R, Lemiere F, Dongen W, Esmans E, Slegers H. Short capillary ion-pair high-performance liquid chromatography coupled to electrospray (tandem) mass spectrometry for the simultaneous analysis of nucleoside mono-, di- and triphosphates. Rapid Commun Mass Spectrom 2002;16:1205-15.
130. Becher F, Pruvost A, Gale J, et al. A strategy for liquid chromatography/tandem mass spectrometric assays of intracellular drugs: application to the validation of the triphosphorylated anabolite of antiretrovirals in peripheral blood mononuclear cells. J Mass Spectrom 2003;38:879-90.
131. Slusher J, Kuwahara S, Hamzeh F, Lewis L, Kornhauser D, Lietman P. Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography-radioimmunoassay procedure. Antimicrob Agents Chemother 1992;36:2473-7.
132. Peter K, Lalezari J, Pearl J, Thevanayagam L, Gambertoglio J. Comparison of zidovudine phosphorylation in lymph nodes and peripheral blood mononuclear cells in HIV-infected patients. DATRI 012 Study Group. AIDS 1998;12:1729-31.
133. Robbins B, Rodman J, McDonald C, Srinivas R, Flynn P, Fridland A. Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells. Antimicrob Agents Chemother 1994; 38:115-21.
134. Robbins B, Waibel B, Fridland A. Quantitation of intracellular zidovudine phosphates by use of combined cartridge-radioimmunoassay methodology. Antimicrob Agents Chemother 1996;40:2651-4.
135. Robbins B, Tran T, Pinkerton, et al. Development of a new cartridge radioimmunoassay for determination of intracellular levels of lamivudine triphosphate in the peripheral blood mononuclear cells of HIV-infected patients. Antimicrob Agents Chemother 1998;42:2656-60.
136. Tran T, Robbins B, Pinkerton F, Ferrua B, Grassi J, Fridland A. A new sensitive cartridge-RIA method for determination of stavudine (D4T) triphosphate in human cells in vivo. Antiviral Res 2003;58:125-9.
137. Moore K, Barrett J, Shaw S, et al. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS 1999;13:2239-50.
138. Robbins B, Tran T, Pinkerton F, et al. Development of a new cartridge radioimmunoassay for determination of intracellular levels of lamivudine triphosphate in the peripheral blood mononuclear cells of HIV-infected patients. Antimicrob Agents Chemother 1998;42:2656-60.
139. Rodman J, Flynn P, Robbins B, et al. Systemic pharmacokinetics and cellular pharmacology of zidovudine in HIV type 1-infected women and newborn infants. J Infect Dis 1999;180:1844-50.
140. Lavie A, Konrad M. Structural requirements for efficient phosphorylation of nucleotide analogs by human thymidylate kinase. Mini Rev Med Chem 2004;4:351-9.
141. Rodriguez J, Rodriguez J, Santana J, Garcia H, Rosario O. Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in HIV-infected individuals. Antimicrob Agents Chemother 2000;44:3097-100.
142. Becher F, Landman R, Mboup S, et al. Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients. AIDS 2004;18:181-7.
143. Daluge S, Good S, Faletto M, et al. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-HIV activity. Antimicrob Agents Chemother 1997;41:1082-93.
144. Harris M, Back D, Kewn S, Jutha S, Marina R, Montaner J. Intracellular carbovir triphosphate levels in patients taking abacavir once a day. AIDS 2002;16:1196-7.
145. Kewn S, Hoggard P, Sales S, et al. Development of enzymatic assays for quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from HIV-infected patients. Antimicrob Agents Chemother 2002;46:135-43.
146. Piliero P, Shachoy-Clark A, Para M, et al. A study examining the pharmacokinetics of abacavir and the intracellular carbovir triphosphate (GSK protocol CNA10905). In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 September 14-17; Chicago, IL, USA; 2003.
147. Krejcova R, Kvetoslava H, Votruba I, Holy A. Phosphorylation of purine (phosphonomethoxy) alkyl derivatives by mitochondrial AMP kinase (AK2 type) from L1210 cells. Collect Czech Chem Commun 2000;65:1653-68.
148. Robbins B, Srinivas R, Kim C, Bischofberger N, Fridland A. Anti-HIV activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother 1998;42:612-7.
149. Darque A, Valette G, Rousseau F, Wang L, Sommadossi J, Zhou X. Quantitation of intracellular triphosphate of emtricitabine in peripheral blood mononuclear cells from HIV-infected patients. Antimicrob Agents Chemother 1999;43:2245-50.
150. Furman P, Davis M, Liotta D, et al. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother 1992;36:2686-92.
151. Rousseau F, Kahn J, Thompson M, et al. Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). J Antimicrob Chemother 2001;48:507-13.
152. Retrovir Prescribing Information. (Accessed August 8, 2004, at http://www.gsk.com/products/retrovir_us.htm)
153. Videx EC Prescribing Information. (Accessed August 8, 2004, at http://www.bms.com/cgi-bin/anybin.pl?sql=select%20PP%20from%20TB_ PRODUCT_PPI%20where%20PPI_SEQ=87&key=PPI
154. Hivid Prescribing Information. (Accessed August 8, 2004, at http://www.rocheusa.com/products/hivid/pi.pdf)
155. Zerit Prescribing Information. (Accessed August 8, 2004, at http://www.bms.com/cgi-bin/anybin.pl?sql=select%20PPI%20from%20TB_ PRODUCT_PPI%20where%20PPI_SEQ=22&key=PPI
156. Cretton E, Zhou Z, Kidd L, et al. In vitro and in vivo disposition and metabolism of 3′-deoxy-2′,3′-didehydrothymidine. Antimicrob Agents Chemother 1993;37:1816-25.
157. Shi J, Ray A, Mathew J, Anderson K, Chu C, Schinazi R. 2(′),3(′)-didehydro-2(′),3(′)-dideoxynucleosides are degraded to furfural alcohol under acidic conditions. Bioorg Med Chem Lett 2004;14:2159-62.
158. Epivir Prescribing Information. (Accessed August 8, 2004, at http://www.gsk.com/products/epivir_us.htm)
159. Viread Prescribing Information. (Accessed August 10, 2004, at http://www.gilead.com/pdf/viread_pi.pdf)
160. Emtriva Prescribing Information. (Accessed August 11, 2004, at http://www.gilead.com/pdf/emtriva_pi.pdf)
161. Frick L, St John L, Taylor L, et al. Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against HIV and hepatitis B virus. Antimicrob Agents Chemother 1993;37:2285-92.
162. Bang L, Scott L. Emtricitabine: an antiretroviral agent for HIV infection. Drugs 2003;63:2413-24.
163. Merrill D, Moonis M, Chou T, Hirsch M. Lamivudine or stavudine in two- and three-drug combinations against HIV type 1 replication in vitro. J Infect Dis 1996;173:355-64.
164. Snyder S, D'Argenio D, Weislow O, Bilello J, Drusano G. The triple combination indinavir-zidovudine-lamivudine is highly synergistic. Antimicrob Agents Chemother 2000;44:1051-8.
165. Veal G, Hoggard P, Barry M, Khoo S, Back D. Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation. Aids 1996;10:546-8.